Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers
Launched by CHULALONGKORN UNIVERSITY · Feb 20, 2017
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
66 participants with overweight received a resveratrol and lipoic acid transdermal patch treatment. The treatment areas have been treated including left and right arms. Subjects were evaluated using standardized measurements of body weight and circumference of arms at baseline and 2 weeks follow-up visits. Evaluation of physician were also measured.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy volunteers with BMI \> 23
- Exclusion Criteria:
- • resveratrol or lipoic acid allergies
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Amornpun Sereemaspun, MD., Ph.D
Study Director
Chulalongkorn University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials